As we gear up for the final stretch of the year, BioLizard enters the autumn season with renewed energy and momentum. The company has delivered a standout first half of 2025, marked by international recognition, groundbreaking AI innovation, and strategic expansion. With major awards, new product developments, and leadership growth, BioLizard is well-positioned to make the remainder of 2025 its most impactful yet.
BioLizard has earned a place in the 2024 EMEA Fast 500 ranking, supported by Deloitte’s prestigious Fast 50 initiative. This independent benchmark celebrates the fastest-growing technology companies across Europe, the Middle East, and Africa, highlighting the entrepreneurial spirit, agility, and innovation that drive the region’s tech ecosystem forward.
Having already distinguished itself as part of the Belgium Technology Fast 50, BioLizard’s inclusion in the broader EMEA Fast 500 list underscores its transition from a national success story to a recognized player on the international stage.
Trends Gazelle 2025 National Selection
BioLizard was selected as a Trends Gazelle 2025, being recognized as one of Belgium’s fastest-growing, most sustainable, and most dynamic companies. This honours our remarkable growth, resilience, and innovation.
For BioLizard, this recognition reflects years of steady progress, scaling its team, expanding its global partnerships, and continuing to pioneer AI-driven solutions for life sciences.
Being named a national-level Gazelle highlights BioLizard’s role as a driving force in Belgium’s thriving biotech and tech ecosystem. The company will join other leaders at the national awards ceremony celebrating Belgium’s entrepreneurial success stories.
Liesbeth Ceelen, CEO of BioLizard, featured prominently on the cover of Trends, underscoring her role as a bold voice in Belgium’s tech and biotech landscape. The feature was tied to a roundtable discussion with some of the country’s leading entrepreneurs and innovators, united under the theme: “Dare. Do. Breakthrough.”
In that conversation, Liesbeth emphasized the importance of courage and adaptability in entrepreneurship, sharing a philosophy that has guided BioLizard’s growth:_"Just don't overthink it, take risks. If it doesn't work, do something else. If it does, all the better."
Her words struck a chord with many in the industry, capturing the essence of what it means to innovate.
Strategic Leadership Expansion: Arjan van Manen joins as Commercial Director and new members join the Advisory board
In January, BioLizard appointed industry veteran Arjan van Manen as Commercial Director, bringing over 20 years of leadership in life sciences. BioLizard’s presence was also spotlighted at Biotech Showcase during JP Morgan Week (January 13–15, 2025) in San Francisco.
In June, we added two new members to our advisory board, Hans Ulrichts and Samuel Pine, bringing in clear value and expertise as we continue to grow and deepen our impact in the life sciences space. They join Paul Vauterin who will continue to contribute his insights as a long-standing SAB member.
VLAIO Grant for AI-Powered Literature Insight Application
In March 2025, BioLizard received a grant from Flanders Innovation & Entrepreneurship (VLAIO) to develop a novel AI tool that leverages large language models (LLMs) to search, extract, and structure insights from vast scientific literature.
Eurostars Grant Collaboration with Broken String Biosciences
In July, BioLizard secured support through a Eurostars grant to apply its AI expertise to Broken String Biosciences’ INDUCE-seq® platform, furthering innovation in sequencing technologies.